OmniAb, Inc. (NASDAQ:OABI) Insider Charles S. Berkman Sells 25,489 Shares

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

OmniAb Price Performance

OABI opened at $3.20 on Friday. The business’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $4.06. OmniAb, Inc. has a 52 week low of $3.11 and a 52 week high of $6.55. The firm has a market cap of $451.89 million, a P/E ratio of -5.16 and a beta of -0.10.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and issued a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

Several hedge funds have recently modified their holdings of OABI. Murchinson Ltd. purchased a new position in shares of OmniAb during the third quarter valued at approximately $4,230,000. Dimensional Fund Advisors LP raised its holdings in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after acquiring an additional 194,835 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of OmniAb by 6.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of OmniAb during the second quarter worth $449,000. Finally, Barclays PLC grew its position in shares of OmniAb by 321.5% in the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the period. 72.08% of the stock is owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.